SEC Company Response from enVVeno Medical (NVNO) — Jun 18, 2018
enVVeno Medical Corp
Date: June 18, 2018 · CIK: 0001661053 · Accession: 0001493152-18-008849
AI Filing Summary & Sentiment
File numbers found in text: 333-225570
Show Raw Text
CORRESP
1
filename1.htm
Hancock
Jaffe Laboratories, Inc.
70
Doppler
Irvine,
California 92618
June
18, 2018
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attn:
Amanda Ravitz
Re:
Hancock
Jaffe Laboratories, Inc.
Registration
Statement on Form S-1
File
No. 333-225570
Request
for Acceleration
Acceleration
Request
Request
Date: June 20, 2018
Request
Time: 4:00 p.m. Eastern Time (or as soon thereafter as practicable)
Dear
Ms. Ravitz:
Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc., a Delaware corporation
(the “Registrant”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-225570), to become effective
at 4:00 p.m. Eastern Time on June 20, 2018, or as soon thereafter as practicable, or at such later time as the Registrant or its
counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes K&L Gates LLP,
counsel to the Registrant, to orally modify or withdraw this request for acceleration.
The
Registrant requests that it be notified of such effectiveness by a telephone call to Michael A. Hedge at (949) 623-3519, or in
his absence, Jason C. Dreibelbis at (949) 623-3543.
Sincerely,
HANCOCK
JAFFE LABORATORIES, INC.
By:
/s/
Robert A. Berman
Robert
A. Berman
Chief
Executive Officer
cc:
Yury
Zhivilo, Hancock Jaffe Laboratories, Inc.
Bill
Abbott, Hancock Jaffe Laboratories, Inc.
Michael
A. Hedge, K&L Gates LLP